PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7011284

Steroid-responsive bilateral sensorineural hearing loss and immune complexes.

J Kanzaki·T Ouchi
View original source ↗Export metadata ↓

Abstract

We have recognized in recent years that some cases with idiopathic bilateral sensorineural hearing loss which showed acute progression in either ear responded to steroid and that the improved hearing level could be maintained by longterm administration of steroid only. Forty cases of bilateral sensorineural hearing loss were selected for study. In most of these cases hearing deterioration of either ear was confirmed by audiometry. Eight of fifteen cases with marked improvement have been proved to respond to steroid treatment. These eight cases include three cases with syphilitic deafness and one case with aortitis syndrome. In four other cases the causes are still unknown, but could be due to autoimmune mechanisms. In four of 25 cases the immune complexes (IC) value was higher than normal and three among them responded to steroid. Since a high IC value has been reported in lupus nephritis, immunologic examinations are necessary for patients over 30 years of age with bilateral sensorineural hearing loss.

Explore related subjects

Adrenal Cortex HormonesAntigen-Antibody ComplexAortitisAutoimmune DiseasesComplement System ProteinsFemaleFluorescent Antibody TechniqueHearing Loss, SensorineuralHumansImmunoglobulinsMalePrednisoloneSyphilisJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Kanzaki, T Ouchi. 1981. Steroid-responsive bilateral sensorineural hearing loss and immune complexes.. https://doi.org/10.1007/bf00665374

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗
PubMed2007

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗